share_log

康方生物：截至二零二四年一月三十一日止月份股份發行人的證券變動月報表

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024

香港交易所 ·  Feb 6 05:13
Summary by Moomoo AI
康方生物科技（開曼）有限公司於2024年2月6日向香港交易及結算所有限公司提交了截至2024年1月31日的證券變動月報表。報告顯示，公司的法定/註冊股本在1月份未發生變動，結存總額維持在5,000,000,000股，面值0.00001美元，法定/註冊股本總額為50,000美元。此外，公司的已發行股份也未見增減，並確認所有證券發行均獲董事會授權批准，且符合相關上市規則要求。報告中提及的股份期權計劃，包括2022年6月28日採納的首次公開發售後購股權計劃，本月內無變動，結存股份期權數目為450,000，可能發行的新股份數目為39,000股。
康方生物科技（開曼）有限公司於2024年2月6日向香港交易及結算所有限公司提交了截至2024年1月31日的證券變動月報表。報告顯示，公司的法定/註冊股本在1月份未發生變動，結存總額維持在5,000,000,000股，面值0.00001美元，法定/註冊股本總額為50,000美元。此外，公司的已發行股份也未見增減，並確認所有證券發行均獲董事會授權批准，且符合相關上市規則要求。報告中提及的股份期權計劃，包括2022年6月28日採納的首次公開發售後購股權計劃，本月內無變動，結存股份期權數目為450,000，可能發行的新股份數目為39,000股。
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 6 February 2024 with Hong Kong Trading and Settlement Limited its Monthly Securities Change Report for the year ended 31 January 2024. The report showed that the company's regulated/registered share capital remained unchanged in January, with a total deposit of 5,000,000,000 shares with an face value of $0.00001 and a total regulated/registered share capital of $50,000. In addition, the company's issued shares were not increased and it was confirmed that all securities issues were approved by the Board of Directors and met the requirements of the relevant Listing Rules. The share option plans referred to in the report, including the Initial Public Offering and Possession Option Plan adopted on June 28, 2022, were unchanged during the month, with 450,000 outstanding share options and 39,000 shares that may be issued.
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 6 February 2024 with Hong Kong Trading and Settlement Limited its Monthly Securities Change Report for the year ended 31 January 2024. The report showed that the company's regulated/registered share capital remained unchanged in January, with a total deposit of 5,000,000,000 shares with an face value of $0.00001 and a total regulated/registered share capital of $50,000. In addition, the company's issued shares were not increased and it was confirmed that all securities issues were approved by the Board of Directors and met the requirements of the relevant Listing Rules. The share option plans referred to in the report, including the Initial Public Offering and Possession Option Plan adopted on June 28, 2022, were unchanged during the month, with 450,000 outstanding share options and 39,000 shares that may be issued.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more